Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy

MEJ Reinders*, Marieke Rhijn, M Khairoun, E Lievers, DK de Vries, AFM Schaapherder, SWS Wong, JJ Zwaginga, JM Duijs, AJ Zonneveld, Martin Hoogduijn, WE Fibbe, JW de Fijter, C van Kooten, TJ Rabelink, H Roelofs

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

44 Citations (Scopus)

Abstract

BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) are pluripotent cells that have immunosuppressive and reparative properties in vitro and in vivo. Although autologous bone marrow (BM)-derived MSCs are already clinically tested in transplant recipients, it is unclear whether these BM cells are affected by renal disease. We assessed whether renal failure affected the function and therapeutic potential of BM-MSCs.

METHODS: MSCs from 10 adults with end-stage renal disease (ESRD) and 10 age-matched healthy controls were expanded from BM aspirates and tested for phenotype and functionality in vitro.

RESULTS: MSCs from ESRD patients were >90% positive for CD73, CD90 and CD105 and negative for CD34 and CD45 and showed a similar morphology and differentiation capacity as MSCs from healthy controls. Of importance for their clinical utility, growth characteristics were similar in both groups, and sufficient numbers of MSCs were obtained within 4 weeks. Messenger RNA expression levels of self-renewal genes and factors involved in repair and inflammation were also comparable between both groups. Likewise, microRNA expression profiling showed a broad overlap between ESRD and healthy donor MSCs. ESRD MSCs displayed the same immunosuppressive capacities as healthy control MSCs, demonstrated by a similar dose-dependent inhibition of peripheral blood mononuclear cell proliferation, similar inhibition of proinflammatory cytokines tumor necrosis factor-α and interferon-γ production and a concomitant increase in the production of interleukin-10.

CONCLUSIONS: Expanded BM-MSCs procured from ESRD patients and healthy controls are both phenotypically and functionally similar. These findings are important for the potential autologous clinical application of BM-MSCs in transplant recipients.

Original languageEnglish
Pages (from-to)663-672
Number of pages10
JournalCytotherapy
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 2013

Bibliographical note

Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Research programs

  • EMC MM-04-39-05

Fingerprint

Dive into the research topics of 'Bone marrow-derived mesenchymal stromal cells from patients with end-stage renal disease are suitable for autologous therapy'. Together they form a unique fingerprint.

Cite this